Pyxis Oncology, Inc. Financial Ratios
PYXS|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-64.0%
Profit Margin
-478.9%
Net Income / Revenue
Asset Turnover
0.18
Revenue / Total Assets
Equity Multiplier
0.76
Total Assets / Equity
Composite: -64.0% (reported: -64.0%)
Profitability
Liquidity
Current Ratio
3.41
Quick Ratio
3.41
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.18
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
-15.8%
-13.9pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.